NCT00444015View on ClinicalTrials.gov

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG

Erlotinib in combination with Dasatinib

6 Cycles @ 28 Days

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER